Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
Background Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight...
Main Authors: | Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Endocrine Society
2021-06-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.e-enm.org/upload/pdf/enm-2020-934.pdf |
Similar Items
-
Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01) -
Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01) -
Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01) -
Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)